1. Home
  2. INTT vs ALXO Comparison

INTT vs ALXO Comparison

Compare INTT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo inTest Corporation

INTT

inTest Corporation

SELL

Current Price

$13.01

Market Cap

148.4M

Sector

Technology

ML Signal

SELL

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$0.99

Market Cap

172.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTT
ALXO
Founded
1981
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
148.4M
172.8M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
INTT
ALXO
Price
$13.01
$0.99
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
★ $20.00
$4.60
AVG Volume (30 Days)
114.0K
★ 1.5M
Earning Date
11-06-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 26.36
EPS
★ 0.06
N/A
Revenue
★ $66,801,000.00
N/A
Revenue This Year
$22.35
N/A
Revenue Next Year
$7.07
N/A
P/E Ratio
$217.17
★ N/A
Revenue Growth
★ 66.06
N/A
52 Week Low
$7.07
$0.86
52 Week High
$20.00
$2.66

Technical Indicators

Market Signals
Indicator
INTT
ALXO
Relative Strength Index (RSI) 51.00 31.65
Support Level $12.71 N/A
Resistance Level $15.25 $2.19
Average True Range (ATR) 0.82 0.13
MACD 0.06 -0.01
Stochastic Oscillator 41.92 24.79

Price Performance

Historical Comparison
INTT
ALXO

About INTT inTest Corporation

inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: